Clinical Report: Ralinepag in pulmonary arterial hypertension
Overview
In the phase 3 ADVANCE OUTCOMES trial, ralinepag significantly reduced the incidence of first clinical worsening events in patients with pulmonary arterial hypertension compared to placebo. Ralinepag was associated with changes in N-terminal pro-B-type natriuretic peptide concentrations and 6-minute walk distance.
Background
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, leading to significant morbidity and mortality. Effective treatment options are crucial for improving patient outcomes and quality of life.
Data Highlights
| Outcome | Ralinepag | Placebo |
|---|---|---|
| First clinical worsening event | 18% | 36% |
| Disease progression | 3% | 11% |
| Initiation of parenteral or inhaled therapy | 3% | 7% |
| Unsatisfactory long-term clinical response | 4% | 10% |
| Mean 6MWD change | +8 m | -12 m |
Key Findings
- Ralinepag reduced the first clinical worsening event rate to 18% compared to 36% for placebo.
- Only 3% of patients on ralinepag experienced disease progression versus 11% on placebo.
- At week 28, N-terminal pro-B-type natriuretic peptide concentrations decreased by 4% with ralinepag, while increasing by 26% with placebo.
- The mean 6-minute walk distance improved by 8 m in the ralinepag group compared to a decrease of 12 m in the placebo group.
- Adverse events led to treatment discontinuation in 19% of ralinepag patients compared to 3% in the placebo group.
Clinical Implications
Clinicians should evaluate treatment options for PAH based on the findings of the ADVANCE OUTCOMES trial.
Conclusion
Ralinepag demonstrates significant efficacy in reducing clinical worsening events in patients with PAH compared to placebo.
Related Resources & Content
- McLaughlin, V.V., et al., ADVANCE OUTCOMES trial, 2023 -- Ralinepag in pulmonary arterial hypertension
- Intensive Care Medicine — Routine Use of Sildenafil in ARDS Patients Remains Unsubstantiated for Now
- reuters — Treprostinil Approval Stalled by FDA
- Clinical Research in Cardiology — Understanding the Action Mechanism of Ranolazine, a Novel Anti-Ischemic Agent
- Pediatric Cardiology — Off-Label Sotatercept Use in Pediatric Pulmonary Arterial Hypertension: A Single-Center Retrospective Hemodynamic Study
- Routine Use of Sildenafil in ARDS Patients Remains Unsubstantiated for Now
- Treprostinil Approval Stalled by FDA
- Understanding the Action Mechanism of Ranolazine, a Novel Anti-Ischemic Agent
- Off-Label Sotatercept Use in Pediatric Pulmonary Arterial Hypertension: A Single-Center Retrospective Hemodynamic Study
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
- https://academic.oup.com/eurheartj/article/44/10/792/7022121?login=false
- https://eprints.gla.ac.uk/391787/1/391787.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
